Fostamatinib disodium is under clinical development by Rigel Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) Pneumonia have an 8% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Fostamatinib disodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fostamatinib disodium overview
Fostamatinib disodium (Tavalisse, Tavlesse) is an immunomodulating agent. It is formulated as film-coated tablets for oral route of administration. Tavalisse is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
It is also under development for the treatment of hidradenitis suppurativa, myelofibrosis with severe thrombocytopenia, pneimonia due to COVID-19 disease, graft versus host disease (GVHD), platinum-resistant ovarian, fallopian tube, antibody mediated rejection in renal transplantation, pancreatic ductal adenocarcinoma and primary peritoneal cancer.It was also under development for the treatment of IgA nephropathy (Berger's disease), rheumatoid arthritis, systemic lupus erythematosus (SLE) and hematological malignancies such as diffuse large B-Cell lymphoma, relapsed or refractory T-Cell lymphoma, acquired (autoimmune) hemolytic anemia.
Rigel Pharmaceuticals overview
Rigel Pharmaceuticals (Rigel) is a biotechnology company. It focuses on discovering, developing and providing novel therapies for the treatment of hematologic disorders and cancer. The company provides fostamatinib disodium hexahydrate tablets, an oral spleen tyrosine kinase inhibitor, to treat adult patients with chronic immune thrombocytopenia, olutasidenib capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and pralsetinib capsules for the treatment of adult patients with non-small cell lung cancer (NSCLC). The company also has partnered for clinical programs with BerGenBio, Daiichi Sankyo, and Eli Lilly. Rigel is headquartered in South San Francisco, California, the US.
For a complete picture of Fostamatinib disodium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
